Literature DB >> 23463330

Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma.

Luca Giovanella1, Pierpaolo Trimboli, Frederik A Verburg, Giorgio Treglia, Arnoldo Piccardo, Luca Foppiani, Luca Ceriani.   

Abstract

PURPOSE: To assess the relationship between serum thyroglobulin (Tg) levels, Tg doubling time (Tg-DT) and the diagnostic performance of (18)F-FDG PET/CT in detecting recurrences of (131)I-negative differentiated thyroid carcinoma (DTC).
METHODS: Included in the present study were 102 patients with DTC. All patients were treated by thyroid ablation (e.g. thyroidectomy and (131)I), and underwent (18)F-FDG PET/CT due to detectable Tg levels and negative conventional imaging. Consecutive serum Tg measurements performed before the (18)F-FDG PET/CT examination were used for Tg-DT calculation. The (18)F-FDG PET/CT results were assessed as true or false after histological and/or clinical follow-up.
RESULTS: Serum Tg levels were higher in patients with a positive (18)F-FDG PET/CT scan (median 6.7 ng/mL, range 0.7-73.6 ng/mL) than in patients with a negative scan (median 1.8 ng/mL, range 0.5-4.9 ng/mL; P < 0.001). In 43 (88 %) of 49 patients with a true-positive (18)F-FDG PET/CT scan, the Tg levels were >5.5 ng/mL, and in 31 (74 %) of 42 patients with a true-negative (18)F-FDG PET/CT scan, the Tg levels were ≤5.5 ng/mL. A Tg-DT of <1 year was found in 46 of 49 patients (94 %) with a true-positive (18)F-FDG PET/CT scan, and 40 of 42 patients (95 %) with a true-negative scan had a stable or increased Tg-DT. Moreover, combining Tg levels and Tg-DT as selection criteria correctly distinguished between patients with a positive and a negative scan (P<0.0001).
CONCLUSION: The accuracy of (18)F-FDG PET/CT significantly improves when the serum Tg level is above 5.5 ng/mL during levothyroxine treatment or when the Tg-DT is less than 1 year, independent of the absolute value.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23463330     DOI: 10.1007/s00259-013-2370-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

1.  Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

Authors:  Markus Luster; Wolfram Karges; Katrin Zeich; Sandra Pauls; Frederik A Verburg; Henning Dralle; Gerhard Glatting; Andreas K Buck; Christoph Solbach; Bernd Neumaier; Sven N Reske; Felix M Mottaghy
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

2.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 4.  The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview.

Authors:  Giorgio Treglia; Barbara Muoio; Luca Giovanella; Massimo Salvatori
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-02       Impact factor: 2.503

5.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.

Authors:  M Dietlein; K Scheidhauer; E Voth; P Theissen; H Schicha
Journal:  Eur J Nucl Med       Date:  1997-11

6.  Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.

Authors:  Luca Giovanella; Luca Ceriani; Diego De Palma; Sergio Suriano; Massimo Castellani; Frederik A Verburg
Journal:  Head Neck       Date:  2011-08-17       Impact factor: 3.147

Review 7.  Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.

Authors:  V Fatourechi; I D Hay
Journal:  Semin Nucl Med       Date:  2000-04       Impact factor: 4.446

Review 8.  Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review.

Authors:  Mia E Miller; Qiaolin Chen; David Elashoff; Elliot Abemayor; Maie St John
Journal:  Head Neck       Date:  2011-04       Impact factor: 3.147

9.  The influence of thyroglobulin on functional imaging in differentiated thyroid cancer.

Authors:  C Menzel; K Zaplatnikov; M Diehl; N Döbert; N Hamscho; F Grünwald
Journal:  Nucl Med Commun       Date:  2004-03       Impact factor: 1.690

10.  Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma.

Authors:  Luca Giovanella; Franco Keller; Luca Ceriani; Renato Tozzoli
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

View more
  20 in total

1.  Papillary Thyroid Carcinoma Metastasis to the Lumbar Spine Masquerading as a Schmorl's Node.

Authors:  Cory P Daignault; Edwin L Palmer; James A Scott; John S Swan; Gilbert H Daniels
Journal:  Nucl Med Mol Imaging       Date:  2015-02-03

2.  The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.

Authors:  Marie Terroir; Isabelle Borget; François Bidault; Marcel Ricard; Frédéric Deschamps; Dana Hartl; Lambros Tselikas; Laurent Dercle; Jean Lumbroso; Eric Baudin; Amandine Berdelou; Désirée Deandreis; Martin Schlumberger; Sophie Leboulleux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-29       Impact factor: 9.236

Review 3.  PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art.

Authors:  Arnoldo Piccardo; Pierpaolo Trimboli; Luca Foppiani; Giorgio Treglia; Giulia Ferrarazzo; Michela Massollo; Gianluca Bottoni; Luca Giovanella
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

4.  The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.

Authors:  E M Triviño Ibáñez; M A Muros; E Torres Vela; J M Llamas Elvira
Journal:  Endocrine       Date:  2015-07-30       Impact factor: 3.633

5.  Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.

Authors:  Arnoldo Piccardo; Matteo Puntoni; Gianluca Bottoni; Giorgio Treglia; Luca Foppiani; Mattia Bertoli; Ugo Catrambone; Anselmo Arlandini; Bassam Dib; Vania Altrinetti; Michela Massollo; Irene Bossert; Manlio Cabria; Francesco Bertagna; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-14       Impact factor: 9.236

6.  Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.

Authors:  Johanna Wassermann; Marie-Odile Bernier; Jean-Philippe Spano; Charlotte Lepoutre-Lussey; Camille Buffet; Jean-Marc Simon; Fabrice Ménégaux; Frédérique Tissier; Monique Leban; Laurence Leenhardt
Journal:  Oncologist       Date:  2015-12-16

7.  Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.

Authors:  Carole Spencer; Ivana Petrovic; Shireen Fatemi; Jonathan LoPresti
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

8.  Correlation of Consecutive Serum Thyroglobulin Levels During Hormone Withdrawal and Failure of Initial Radioiodine Ablation in Thyroid Cancer Patients.

Authors:  Hyukjin Yoon; Sung Hoon Kim; Joo Hyun O; Ye Young Seo; Yeongjoo Lee; Hyoungwoo Kim; Jiyoung Ryu
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01

9.  Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Friederike Schütz; Christine Lautenschläger; Kerstin Lorenz; Johannes Haerting
Journal:  Eur Thyroid J       Date:  2017-10-24

Review 10.  How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.

Authors:  Carole Spencer; Jonathan LoPresti; Shireen Fatemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.